Mumbai, India – Wanbury Limited, a leading pharmaceutical company with a significant presence in the global API market and domestic branded formulations, is pleased to announce the launch of two new products this month. The company will introduce C-RED, a branded generic hematinic iron tablet under its formulations division, and Ketamine Hydrochloride under its API (Active Pharmaceutical Ingredient) division.

C-RED: A New Solution for Iron Deficiency

Leveraging its strong equity in the gynecology segment, Wanbury is launching C-RED to address iron deficiency and improve hemoglobin levels, particularly among pregnant women. The new iron supplement contains Liposomal Iron, offering superior absorption, reduced gastric irritation, and minimal side effects compared to conventional iron salts. This innovation ensures faster hemoglobin rise without oxidative damage, providing an effective and well-tolerated solution for anemia management.

The prevalence of anemia remains a significant health challenge in India, affecting over 40% of both men and women. Wanbury’s C-RED builds on its legacy following the success of its previous brand C Pink, which was divested during the company’s debt settlement.

Ketamine Hydrochloride API: Expanding Global Reach

Wanbury’s Ketamine Hydrochloride API has been developed using a cost-effective, high-quality process by the company’s in-house R&D team, adhering to major pharmacopeia standards, including USP and EP. Ketamine is widely used as an anesthetic for both human and veterinary applications, with an annual global demand exceeding 200 tons.

This month, Wanbury will commence the export of Ketamine Hydrochloride to the European market, marking a significant milestone in the company’s API expansion strategy.

With these launches, Wanbury continues to strengthen its product portfolio and reinforce its commitment to delivering innovative and accessible healthcare solutions.